“Anavex’s (AVXL) portfolio with non-invasive targeted upstream precision compounds continues to advance with special focus on Alzheimer’s disease and schizophrenia. We also continue to receive feedback from neurologists preferring convenient orally available and clinically meaningful Alzheimer’s disease treatment options, which can be accessed without logistical restrictions,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. “Furthermore, we were excited to recently present open-label-extension data of blarcamesine for Alzheimer’s disease at AD/PD(TM) 2025, which confirmed continued clinically meaningful benefit for early Alzheimer’s disease patients.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVXL:
- Largest borrow rate increases among liquid names
- Anavex Life Sciences (AVXL) Q2 Earnings Cheat Sheet
- Anavex Life Sciences: Promising Developments and Strategic Growth Opportunities Justify Buy Rating
- Anavex announces full enrollment fo Phase 2 study of ANAVEX 3-71
- Anavex appoints Audrey Gabelle to Scientific Advisory Board
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue